Reduce freezing episodes using Cue2Walk
- Trial ID
- NCT06416345
- Official Title
- Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care in People With Parkinson's Disease
- Goal
- Reduce freezing episodes using Cue2Walk
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Amsterdam UMC, location VUmc
- Study Type
- INTERVENTIONAL
- Enrollment
- 84 participants
- Conditions
- Parkinson Disease
- Interventions
- Cue2Walk, Usual Care
Plain-Language Summary
The goal is to reduce daily freezing of gait and see if an automated cueing system is more effective and cost efficient than usual care. Cue2Walk is a wearable system that automatically detects freezing episodes and delivers timed external cues, like rhythmic sounds or vibrations, to help restart and regularize stepping; it is meant to work alongside your current treatments and does not replace levodopa or DBS. The trial seeks people with Parkinson's diagnosed by UK Brain Bank criteria who have daily freezing, are Hoehn and Yahr stage 2 to 4, have stable medication or DBS settings, and can walk five minutes unassisted. People who already use a personal cueing device, have had prior Cue2Walk use, are in another study, or have cognitive impairment preventing understanding instructions (MoCA score under 16) are excluded.
Locations
- Radboudumc, Nijmegen, Gelderland, Netherlands
- Amsterdam UMC, location VUmc, Amsterdam, North Holland, Netherlands
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Cue2Walk. The goal is to reduce daily freezing of gait and see if an automated cueing system is more effective and cost efficient than usual care. Cue2Walk is a wearable system that automatically detects freezing episodes and delivers timed external cues, like rhythmic sounds or vibrations, to help restart and regularize stepping; it is meant to work alongside your current treatments and does not replace levodopa or DBS. The trial seeks people with Parkinson's diagnosed by UK Brain Bank criteria who have daily freezing, are Hoehn and Yahr stage 2 to 4, have stable medication or DBS settings, and can walk five minutes unassisted. People who already use a personal cueing device, have had prior Cue2Walk use, are in another study, or have cognitive impairment preventing understanding instructions (MoCA score under 16) are excluded.
- Who can participate?
- Eligibility criteria vary. Check the full listing on ClinicalTrials.gov for detailed inclusion and exclusion criteria.
- Where is this trial located?
- This trial is recruiting at 2 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 3 months.